{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:57:06Z","timestamp":1772161026735,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2002,9,27]],"date-time":"2002-09-27T00:00:00Z","timestamp":1033084800000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Two simulation models were developed to analyze the cost\u2010effectiveness of new treatments that affect the progression of rheumatoid arthritis (RA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used data from 2 cohorts of patients with early RA who had been followed up since disease onset (up to 15 years). In the Swedish study, 183 patients were followed up for a mean of 11.3 years. In the UK study, 916 patients were followed up for a mean of 7.8 years. Disease progression over 10 years was modeled as annual transitions between disease states, defined by Health Assessment Questionnaire (HAQ) scores. A regression model was used to estimate transition probabilities conditional on age, sex, and time since onset of disease, in order to allow simulation of different patient cohorts. Costs and utilities associated with different HAQ levels were based on data from the cohort studies and cross\u2010sectional surveys.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Costs increase and quality of life decreases as RA progresses. In Sweden, total annual costs range from $4,900 to $33,000 per patient, compared with $4,900 to $14,600 in the UK. Cumulative costs over 10 years for patients starting in disease state 1 (HAQ &lt; 0.6) are $54,600 in Sweden and $26,600 in the UK. The cumulative numbers of quality\u2010adjusted life\u2010years (QALYs) are 5.5 and 5.6, respectively. Both costs and QALYs were discounted at 3%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The 2 models, which were based on different patient cohorts, reach a similar conclusion in terms of the effect of RA over 10 years. They appear to accurately capture disease progression and its effects and can therefore be useful in estimating the cost\u2010effectiveness of new treatments in RA.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.10471","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T04:45:25Z","timestamp":1034138725000},"page":"2310-2319","source":"Crossref","is-referenced-by-count":95,"title":["Modeling the progression of rheumatoid arthritis: A two\u2010country model to estimate costs and consequences of rheumatoid arthritis"],"prefix":"10.1002","volume":"46","author":[{"given":"Gisela","family":"Kobelt","sequence":"first","affiliation":[]},{"given":"Linus","family":"J\u00f6nsson","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Lindgren","sequence":"additional","affiliation":[]},{"given":"Adam","family":"Young","sequence":"additional","affiliation":[]},{"given":"Kerstin","family":"Eberhardt","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2002,9,27]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780192623560.001.0001","volume-title":"Epidemiology of rheumatic diseases","author":"Silman A","year":"1993"},{"key":"e_1_2_6_3_2","first-page":"131","volume-title":"Rheumatoid arthritis: pathogenesis, assessment, outcome and treatment","author":"Symmons D","year":"1994"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780240315"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199500501-00003"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199406060-00005"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1790080411"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270805"},{"key":"e_1_2_6_9_2","first-page":"44","article-title":"Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset","volume":"25","author":"Fex E","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.335"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.12.1403"},{"key":"e_1_2_6_12_2","first-page":"819","article-title":"The lifetime economic cost of rheumatoid arthritis","volume":"11","author":"Stone CE","year":"1984","journal-title":"J Rheumatol"},{"key":"e_1_2_6_13_2","unstructured":"JoenssonB KaarelaK KobeltG.Economic consequences of disease progression in rheumatoid arthritis in Finland: a Markov model. Stockholm School of Economics EFI research report no. 6574;1997."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300103228"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.8.781"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/36.5.551"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-6822-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195108248.001.0001","volume-title":"Cost\u2010effectiveness in health and medicine","author":"Gold M","year":"1996"},{"key":"e_1_2_6_20_2","volume-title":"Methods for the economic evaluation of health care","author":"Drummond M","year":"1997"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9301300409"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02274837"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.12.1324"},{"key":"e_1_2_6_24_2","article-title":"Ten\u2010year outcome in a cohort of early rheumatoid arthritis patients: health status, disease process and damage","author":"Lindqvist E","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.6.603"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"e_1_2_6_28_2","first-page":"492","article-title":"Mortality in rheumatoid arthritis","volume":"66","author":"Guedes C","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"e_1_2_6_29_2","first-page":"1895","article-title":"Functional status predicts mortality in a community based rheumatoid arthritis population","volume":"25","author":"Soderlin MK","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.1.11"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.12.954"},{"key":"e_1_2_6_32_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol: a new facility for the measurement of health\u2010related quality of life","volume":"16","author":"The Euro Qol Group","year":"1990","journal-title":"Health Policy"},{"key":"e_1_2_6_33_2","volume-title":"A social tariff for EuroQol: results from a UK general population survey","author":"Dolan P","year":"1995"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(96)00822-6"},{"issue":"9","key":"e_1_2_6_35_2","first-page":"S311","article-title":"Costs and effects of leflunomide in the UK","volume":"44","author":"Kobelt G","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"9","key":"e_1_2_6_36_2","first-page":"S312","article-title":"Economic consequences of the progression of rheumatoid arthritis in Sweden and the United Kingdom","volume":"44","author":"Kobelt G","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_37_2","first-page":"1290","article-title":"Clinical and health status measures over time: prognosis and outcome assessment in rheumatoid arthritis","volume":"18","author":"Wolfe F","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_38_2","first-page":"1906","article-title":"Severity of disability and duration of disease in rheumatoid arthritis","volume":"19","author":"Leigh JP","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290406"},{"key":"e_1_2_6_40_2","first-page":"800","article-title":"Disability in patients with early inflammatory polyarthritis cannot be \u201ctracked\u201d from year to year: an examination of the hypothesis underlying percentile reference charts","volume":"26","author":"Wiles N","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_41_2","first-page":"1298","article-title":"The assessment and prediction of functional disability in rheumatoid arthritis","volume":"18","author":"Wolfe F","year":"1991","journal-title":"J Rheumatol"},{"key":"e_1_2_6_42_2","first-page":"1326","article-title":"Inflammatory polyarthritis in the community is not a benign disease: predicting functional disability one year after presentation","volume":"23","author":"Harrison BJ","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_43_2","first-page":"1466","article-title":"Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis?","volume":"22","author":"Van der Heide A","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_44_2","first-page":"1037","article-title":"Functional impairment and disability in early rheumatoid arthritis: development over 5 years","volume":"22","author":"Eberhardt K","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_45_2","first-page":"366","article-title":"Functional disability in rheumatoid arthritis: two different models in early and established disease","volume":"19","author":"Guillemin F","year":"1992","journal-title":"J Rheumatol"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10471","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T07:58:12Z","timestamp":1704614292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1002\/art.10471"],"URL":"https:\/\/doi.org\/10.1002\/art.10471","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}